Mankind Pharma Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Mankind Pharma Share Price

2,372.70-3.50 (-0.15%)

Closed
As On: 11 Jun, 2026, 03:54 PM IST
As On: 11 Jun, 2026, 03:46 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	2,351.10
High	2,409.00
Low	2,350.50
Prev Close	2,376.20
Volume	2,75,897
VWAP(₹)	2,388.21

Key Metrics

PE Ratio(x)	51.21
EPS - TTM(₹)	46.34
MCap(₹ Cr.)	97,951.78
MCap Rank	8
PB Ratio(x)	5.92
Div Yield(%)	0.04
Face Value(₹)	1.00
52W High(₹)	2,716.50
52W Low(₹)	1,909.70
MCap/Sales	5.80
Beta(1 Month)	-
BV/Share(₹)	401.16

Mankind Pharma share price insights

Rank 197 - ET 5002025 ranking

Employee & Interest Expense
Company has spent 4.48% of its operating revenues towards interest expenses and 22.3% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Candle Formations Yesterday
White Spinning Top was formed for Mankind Pharma
Mankind Pharma Share Price Update
Mankind Pharma Ltd. share price moved down by -0.15% from its previous close of Rs 2,376.20. Mankind Pharma Ltd. stock last traded price is 2,372.70
Share Price Value
Today/Current/Last 2,372.702,382.00
Previous Day 2,376.202,371.75

Found Insights useful?

Mankind Pharma Share Price Returns

1 Day	-0.15%
1 Month	-0.26%
3 Months	7.46%
1 Year	-0.72%
3 Years	60.89%
5 Years	N.A.

Mankind Pharma Share Recommendations

Mean recosCurrent

BUY

18 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	4	4	4	5
Buy	7	7	7	6
Hold	3	3	3	3
Sell	3	3	3	3
Strong Sell	1	1	-	-
# Analysts	18	18	17	17

Recent Recos

Target₹2760
OrganizationMotilal Oswal Financial Services
BUY

Target₹2650
OrganizationMotilal Oswal Financial Services
BUY

View all Stock Recommendations

News & Analysis

View all Mankind Pharma Share News & Announcements

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	3,557.22	3,639.95	3,789.03	3,650.23	3,330.70
Total Income Growth (%)	-2.27	-3.93	3.80	9.59	0.71
Total Expenses	2,759.29	2,976.96	2,997.65	2,942.26	2,627.05
Total Expenses Growth (%)	-7.31	-0.69	1.88	12.00	1.33
EBIT	797.93	662.99	791.38	707.97	703.65
EBIT Growth (%)	20.35	-16.22	11.78	0.61	-1.56
Profit after Tax (PAT)	554.35	408.75	511.51	438.32	420.77
PAT Growth (%)	35.62	-20.09	16.70	4.17	10.66
EBIT Margin (%)	22.43	18.21	20.89	19.40	21.13
Net Profit Margin (%)	15.58	11.23	13.50	12.01	12.63
Basic EPS (₹)	13.44	9.90	12.39	10.62	10.20

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	2,708.52	2,689.20	2,686.45	2,605.58	2,345.91
Total Income Growth (%)	0.72	0.10	3.10	11.07	-4.88
Total Expenses	1,795.23	2,045.54	2,014.62	1,965.22	1,754.91
Total Expenses Growth (%)	-12.24	1.53	2.51	11.98	0.70
EBIT	913.29	643.66	671.83	640.36	591.00
EBIT Growth (%)	41.89	-4.19	4.91	8.35	-18.34
Profit after Tax (PAT)	713.61	449.47	458.90	412.76	382.46
PAT Growth (%)	58.77	-2.05	11.18	7.92	-8.15
EBIT Margin (%)	33.72	23.93	25.01	24.58	25.19
Net Profit Margin (%)	26.35	16.71	17.08	15.84	16.30
Basic EPS (₹)	17.29	10.89	11.12	10.00	9.27

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	14,636.43	12,744.23	10,615.63	8,878.00	7,977.58
Total Revenue Growth (%)	14.85	20.05	19.57	11.29	24.94
Total Expenses	12,185.69	10,240.14	8,231.49	7,219.18	6,017.43
Total Expenses Growth (%)	19.00	24.40	14.02	19.97	27.88
Profit after Tax (PAT)	1,912.93	1,990.96	1,912.90	1,281.86	1,433.48
PAT Growth (%)	-3.92	4.08	49.23	-10.58	13.28
Operating Profit Margin (%)	21.64	24.03	23.39	19.46	25.94
Net Profit Margin (%)	13.39	16.30	18.50	14.65	18.42
Basic EPS (₹)	46.35	49.28	47.75	32.00	35.78

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	10,747.28	9,991.01	9,531.45	8,289.94	7,419.77
Total Revenue Growth (%)	7.57	4.82	14.98	11.73	30.68
Total Expenses	8,326.04	7,685.02	7,271.88	6,727.10	5,622.23
Total Expenses Growth (%)	8.34	5.68	8.10	19.65	32.68
Profit after Tax (PAT)	2,037.56	1,945.48	1,823.41	1,248.26	1,335.13
PAT Growth (%)	4.73	6.69	46.08	-6.51	23.12
Operating Profit Margin (%)	28.62	28.19	24.54	19.57	25.37
Net Profit Margin (%)	19.55	20.48	19.68	15.35	18.39
Basic EPS (₹)	49.37	48.16	45.52	31.16	33.33

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 4.48% of its operating revenues towards interest expenses and 22.3% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	28,079.53	27,759.53	11,963.25	9,715.45	9,147.74
Total Assets Growth (%)	1.15	132.04	23.14	6.21	43.55
Total Liabilities	11,518.48	13,191.35	2,387.47	2,092.16	2,831.43
Total Liabilities Growth (%)	-12.68	452.53	14.12	-26.11	87.54
Total Equity	16,561.05	14,568.18	9,575.79	7,623.29	6,316.31
Total Equity Growth (%)	13.68	52.14	25.61	20.69	29.89
Current Ratio (x)	1.10	1.23	3.10	2.32	1.68
Total Debt to Equity (x)	0.39	0.59	0.02	0.02	0.14
Contingent Liabilities	0.00	5,304.33	329.78	167.78	211.93

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	24,625.31	23,828.32	11,417.71	9,371.12	8,412.85
Total Assets Growth (%)	3.34	108.70	21.84	11.39	43.07
Total Liabilities	8,228.37	9,188.05	1,793.90	1,587.21	2,344.07
Total Liabilities Growth (%)	-10.44	412.18	13.02	-32.29	104.53
Total Equity	16,396.94	14,640.27	9,623.81	7,783.91	6,068.77
Total Equity Growth (%)	12.00	52.13	23.64	28.26	28.19
Current Ratio (x)	0.78	1.15	3.45	2.48	1.46
Total Debt to Equity (x)	0.34	0.50	0.00	0.00	0.11
Contingent Liabilities	0.00	4,261.71	449.91	168.37	275.47

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	3,121.29	2,413.38	2,152.45	1,813.30	919.78
Net Cash used in Investing Activities	-196.42	-12,682.95	-2,081.69	-1,054.13	-1,369.14
Net Cash flow from Financing Activities	-2,952.69	10,232.56	5.27	-739.73	604.62
Net Cash Flow	-12.19	21.87	77.19	21.76	155.73
Closing Cash & Cash Equivalent	391.69	403.88	382.01	304.82	283.06
Closing Cash & Cash Equivalent Growth (%)	-3.02	5.73	25.32	7.69	122.31
Total Debt/ CFO (x)	2.02	3.51	0.09	0.09	0.95

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	2,751.99	2,322.16	1,982.97	1,798.99	812.29
Net Cash used in Investing Activities	-387.96	-12,114.68	-1,919.12	-1,040.61	-1,369.34
Net Cash flow from Financing Activities	-2,476.92	9,845.34	-8.68	-710.41	578.92
Net Cash Flow	-113.02	-11.33	55.07	47.96	21.87
Closing Cash & Cash Equivalent	87.66	200.29	189.20	134.13	44.45
Closing Cash & Cash Equivalent Growth (%)	-56.23	5.86	41.06	201.76	-27.76
Total Debt/ CFO (x)	2.02	3.12	0.00	0.00	0.85

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 196.42 cr for investing activities which is an YoY decrease of 98.45%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	11.73	13.89	20.43	17.24	23.28
Return on Capital Employed (%)	14.32	13.27	24.56	21.69	30.94
Return on Assets (%)	6.81	7.17	15.98	13.19	15.67
Interest Coverage Ratio (x)	6.22	8.28	83.98	45.63	37.29
Asset Turnover Ratio (x)	0.51	0.61	0.95	0.88	0.98
Price to Earnings (x)	43.29	50.25	48.31	-	-
Price to Book (x)	5.08	6.98	9.83	-	-
EV/EBITDA (x)	22.36	30.42	32.40	-	-
EBITDA Margin (%)	27.84	29.11	27.24	23.19	28.08

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	12.42	13.28	18.94	16.03	22.00
Return on Capital Employed (%)	15.57	13.56	23.14	20.00	29.77
Return on Assets (%)	8.27	8.16	15.97	13.32	15.87
Interest Coverage Ratio (x)	6.07	8.22	177.88	67.04	44.77
Asset Turnover Ratio (x)	0.43	0.54	0.89	0.91	1.02
Price to Earnings (x)	40.65	51.55	50.51	-	-
Price to Book (x)	5.05	6.83	9.56	-	-
EV/EBITDA (x)	25.85	34.99	35.21	-	-
EBITDA Margin (%)	32.74	32.17	27.97	22.88	27.04

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
42%
Positive Movement
since 1st Jan 2005
on basis
57%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 2404.30 Pivot
2377.40
S1 2345.80
R2 2435.90 S2 2318.90
R3 2494.40 S3 2260.40
Average True Range
5 Days 14 Days 28 Days
60.53 69.72 69.11

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Mankind Pharma	51.21	5.91	11.73	14.32	6.81	17.94	21.64	13.49	46.35	1.10	0.39	2.02
Divis Labs	68.80	10.54	15.32	19.37	12.81	10.79	33.00	24.31	96.75	5.43	0.00	0.00
Torrent Pharma	71.54	8.80	25.78	9.30	4.88	12.70	23.93	15.29	63.92	1.13	1.76	4.90
Cipla	28.80	3.24	11.26	15.65	9.12	7.65	19.72	13.74	48.03	3.44	0.01	0.07
Cadila Healthcare	22.08	3.76	18.58	20.64	9.61	16.47	27.90	18.51	50.09	1.27	0.43	5.56
Add More

Annual Ratios (%)

Choose from Peers

Dr. Reddys
Lupin
Aurobindo Pharma
Biocon
Alkem Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Found Peer Comparison useful?

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 29,99,60,612 72.66 % 0.00
Pledge 0 0.00 % 0.00
FII 4,22,73,430 10.23 % -1.10
DII 5,95,22,517 14.42 % 1.19
MF 4,27,76,437 10.36 % 1.05
Others 1,10,71,769 2.68 % -0.09
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 72.66 72.66 72.67 72.68
Pledge 0.00 0.00 0.00 0.00
FII 10.23 11.34 12.83 13.07
DII 14.42 13.22 11.87 11.46
Mutual Funds 10.36 9.30 7.78 7.34
Others 2.68 2.78 2.62 2.78

Mutual Funds Ownership

MF Ownership as on 30 April 2026

SBI Large Cap Direct-G
Equity: Large Cap
4
- 915.07
  Amount Invested (in Cr.)
- 1.71%
  % of AUM
- 0.00
  % Change (MoM basis)
HDFC Large Cap Direct-G
Equity: Large Cap
4
- 615.48
  Amount Invested (in Cr.)
- 1.61%
  % of AUM
- 0.00
  % Change (MoM basis)
Nippon India Growth Mid Cap Direct-G
Equity: Mid Cap
5
- 516.74
  Amount Invested (in Cr.)
- 1.13%
  % of AUM
- 55.39
  % Change (MoM basis)

View all Mutual Fund Schemes

Mankind Pharma Top Searches

Corporate Actions

Recent
Board Meeting
Audited Results
May 07, 2026
Board Meeting
Quarterly Results
Jan 09, 2026
Board Meeting
Quarterly Results
Oct 27, 2025

Announced on	Meeting on
May 07, 2026	May 19, 2026
Audited Results
Jan 09, 2026	Feb 03, 2026
Quarterly Results
Oct 27, 2025	Nov 06, 2025
Quarterly Results
Jul 14, 2025	Jul 31, 2025
Quarterly Results & Interim Dividend
May 08, 2025	May 21, 2025
Audited Results

Dividends
Announced on Ex-Date Dividend%
Jul 31, 2025 Aug 08, 2025 100%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Jul 03, 2025 Aug 07, 2025
-
Nov 21, 2024 Dec 24, 2024
-
Jul 18, 2024 Aug 09, 2024
-
Aug 02, 2023 Sep 22, 2023
-

About Mankind Pharma

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 97,951.78 Crore) operating in Pharmaceuticals sector.

Mankind Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 3,557.22 Crore, down 2.27 % from last quarter Total Income of Rs 3,639.95 Crore and up 6.80 % from last year same quarter Total Income of Rs 3,330.70 Crore. Company has reported net profit after tax of Rs 556.43 Crore in latest quarter.

The company’s top management includes Mr.Ramesh Juneja, Mr.Rajeev Juneja, Mr.Sheetal Arora, Mr.Satish Kumar Sharma, Ms.Sheetal Arora, Mr.Bharat Anand, Mr.Tilokchand Punamchand Ostwal, Ms.Vijaya Sampath, Mr.Vivek Kalra, Mr.Ashutosh Dhawan, Mr.Arjun Juneja, Mr.Hitesh Kumar Jain. Company has Goel Gaurav & Co. as its auditors. As on 31-03-2026, the company has a total of 41.28 Crore shares outstanding.

Mankind Pharma Share Price Today is Rs. 2372.70. On previous day, the Mankind Pharma Share Price (NSE) closed at Rs. 2376.2, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 72.66% of the stake in Mankind Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Mankind Pharma stocks was 10.24% as compared to 11.34% in Dec 2025 with decrease of 1.1%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 14.42% as compared to 13.22% in Dec 2025 with increase of 1.2%. Out of the total DII holdings in Mankind Pharma shares 10.36% was held by mutual funds. The rest including public held is 2.68%. Mankind Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Mankind Pharma Dividend: Ever since 1991, Mankind Pharma dividends has been paid out around 1 times. As on 11 Jun, 2026, 03:54 PM IST, The overall dividend yield for Mankind Pharma stands at 0.04%. The last dividend paid was on August 8, 2025 (Rs. 1.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 46.34.

Mankind Pharma Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 3557.22 Cr. of sales and 2.27% of quarterly net loss, there have been multiple ups and downs in the Mankind Pharma stock prices in the past few weeks. For example, Mankind Pharma stock price on 4th of June 2026 was around Rs. 2353.0. Mankind Pharma share price now stands at an average of Rs. 2372.70. Judging by last week's performance, stock is in up trend.

Mankind Pharma has a median target price of Rs. 2662.78 in 12 months by 18 analysts. They have provided a high estimate of Rs. 3100.0 and low estimate of Rs. 1990.0 for Mankind Pharma share.

Historical Prices and Performance:
Mankind Pharma, incorporated in 1991 is a Large Cap company (with a market cap of Rs. 97951.78) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Mankind Pharma stock was 11.73%, 13.89%, 20.43%, 17.24% and 23.28% respectively.
The Mankind Pharma share gave a 3 year return of 59.75% as compared to Nifty 50 which gave a return of 24.77%.
Mankind Pharma announced 100.0% final dividend on August 8, 2025.

Key Metrics:
PE Ratio of Mankind Pharma is 51.21
Prices/Sales Ratio of Mankind Pharma is 5.8
Price/Book Ratio of Mankind Pharma is 5.91

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Mankind Pharma, major competitors and peers include Divis Labs, Torrent Pharma, Cipla and Cadila Healthcare. As of Dec 2025, the dividend yield of Mankind Pharma stands at 0.04% while Divis Labs, Torrent Pharma, Cipla and Cadila Healthcare stand at 0.45%, 0.83%, 0.94% and 0.09% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 51.21 and 5.91 respectively.

Recommendations:
The current total number of analysts covering the stock stands at 18, Three months ago this number stood at 17. Out of total, 4 analyst have a'Strong Buy' reco, 7 analyst have a'Buy' reco, 3 analyst have a'Hold' reco, 3 analyst have a'Sell' reco.

Mean recommendations by 18 analyst stand at'Buy'.

Leadership of Mankind Pharma :
Hitesh Kumar Jain is Co. Secretary & Compl. Officer
Ashutosh Dhawan is Global Chief Financial Officer
Arjun Juneja is Chief Operating Officer
Anil Kumar is Chief Scientific Officer
Sanjay Koul is Chief Marketing Officer
Atish Majumdar is Sr. President - Sales and Marketing
Prakash Agarwal is President - Strategy
Sheetal Arora is Chief Executive Officer
Sudipta Roy is Sr. President - Sales and Marketing
Ramesh Juneja is Chairman & Wholetime Director
Rajeev Juneja is Vice Chairman & Mng.Director
Sheetal Arora is Whole Time Director
Satish Kumar Sharma is Whole Time Director
Vivek Kalra is Independent Director
Tilokchand Punamchand Ostwal is Independent Director
Bharat Anand is Independent Director
Vijaya Sampath is Independent Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

Nifty Midcap 50, Nifty Midcap 100, Nifty 200, Nifty 500, BSE 500

Address

208, Okhla Industrial Estate,Phase-III,New Delhi, Delhi - 110020

Contact

investors@mankindpharma.com

http://www.mankindpharma.com

Executive Leadership

RJ

Ramesh Juneja

Chairman & Wholetime Director

RJ

Rajeev Juneja

Vice Chairman & Mng.Director

SA

Sheetal Arora

Chief Executive Officer

SK

Satish Kumar Sharma

Whole Time Director

Show More

Auditors

S R Batliboi & Co. LLP

Bhagi Bhardwaj Gaur & Co

Goel Gaurav & Co.

FAQs about Mankind Pharma share

1. What is Mankind Pharma share price and what are the returns for Mankind Pharma share?
Mankind Pharma share price is Rs 2,372.70 as on 11 Jun, 2026, 03:54 PM IST. Mankind Pharma share price is down by 0.15% based on previous share price of Rs 2,376.2. Mankind Pharma share price trend:
- Last 12 Months: Mankind Pharma share price moved down 0.72%
- Last 3 Years: Mankind Pharma Share price moved up by 60.89%
2. What are the returns for Mankind Pharma share?
Return Performance of Mankind Pharma Shares:
- 1 Week: Mankind Pharma share price moved up by 1.57%
3. What has been highest price of Mankind Pharma share in last 52 weeks?
Mankind Pharma share price saw a 52 week high of Rs 2,716.50 and 52 week low of Rs 1,909.70.
4. What's the market capitalization of Mankind Pharma?
Market Capitalization of Mankind Pharma stock is Rs 97,951.78 Cr.
5. What is the PE & PB ratio of Mankind Pharma?
The PE ratio of Mankind Pharma stands at 51.21, while the PB ratio is 5.91.

Top Gainers

As on 03:59 PM | 11 Jun 2026

Aegis Logistics

925.90

124.90 (15.60%)

111.45

8.52 (8.28%)

DOMS Industries

2,255.40

136.81 (6.46%)

Blue Jet Healthcare

498.45

28.70 (6.11%)

1,923.80

90.80 (4.96%)

Top Losers

As on 03:59 PM | 11 Jun 2026

Balkrishna Ind.

1,974.00

-109.20 (-5.25%)

1,133.10

-60.31 (-5.06%)

155.70

-7.93 (-4.85%)

166.91

-8.00 (-4.57%)

Adani Transmission

1,466.70

-68.90 (-4.49%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.